Same script- Different company. AVI, which became

Same script- Different company. AVI, which became SRPT, was like CYDY currently is like, back in 2016-2018. AVI CEO Garabedian developed loggerheads with the FDA over AVI's one drug. Garabedian was let go and Ed Kaye assumed the role of CEO. His experience and connections helped win a very contentious approval of AVI (SRPT now) drug through the FDA. The dust had hardly settled when Dr. Kaye resigned the CEO spot but remained as CMO for a while. SRPT stock went from a low of $8 to around $170 with the approval..
I suspect CYDY recognized it needed a CEO to get an approval, any approval, for leronlimab and NP wasn't that person. The notice from the CYDY tells us that.
CYDY will be looking for an experienced CEO who has been successful getting a drug across the finish line, which is a different skill set than developing the drug or selling the drug.
Talk about buyout or partnership is premature. CYDY needs Leronlimab to be approved for anything before they can really market the drug to the masses or the company to Big Pharma and receive value for it. Once the approval is history then we'll probably see another CEO come in to either market leronlimab or to sell or partner with Big Pharma..
Whatever the event was that triggered NP's termination will eventually filter out. Those facts usually do, even if it was a series of small differences that culminated in a blow out "my way or the highway" event.
I see the share price rising, then doing some stutter steps, then resuming a rise.
CYDY has good times ahead....as the script suggests.